FDA panel to evaluate Sirion’s Durezol
Executive Summary
FDA's Dermatologic Drugs Advisory Committee will meet May 29 to discuss Sirion Therapeutics' Durezol (difluprednate) for the treatment of inflammation and pain following ocular surgery. The NDA for the topical ophthalmic steroid has a June 26 action date...